QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
Top-Rated StocksTop-Rated
NASDAQ:CBAY

CymaBay Therapeutics (CBAY) Stock Forecast, Price & News

$14.83
+0.51 (+3.56%)
(As of 09/26/2023 ET)
Compare
Today's Range
$14.76
▼
$15.70
50-Day Range
$11.27
▼
$17.62
52-Week Range
$3.15
▼
$18.20
Volume
3.37 million shs
Average Volume
1.91 million shs
Market Capitalization
$1.64 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.18
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

CymaBay Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.08 Rating Score
Upside/​Downside
33.6% Upside
$19.82 Price Target
Short Interest
Healthy
8.12% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
0.53mentions of CymaBay Therapeutics in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$2.17 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.93) to ($1.30) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.79 out of 5 stars

Medical Sector

73rd out of 964 stocks

Pharmaceutical Preparations Industry

17th out of 442 stocks

See Top Rated MarketRank™ Stocks Here

CBAY stock logo

About CymaBay Therapeutics (NASDAQ:CBAY) Stock

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

CBAY Price History

CBAY Stock News Headlines

September 26, 2023 | markets.businessinsider.com
UBS Maintains Buy Rating for CymaBay Therapeutics: Here's What You Need To Know
September 24, 2023 | americanbankingnews.com
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Given Consensus Rating of "Buy" by Analysts
September 26, 2023 | Chaikin Analytics (Ad)
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
September 22, 2023 | markets.businessinsider.com
B.Riley Financial Sticks to Its Buy Rating for CymaBay Therapeutics (CBAY)
September 22, 2023 | americanbankingnews.com
Research Analysts Issue Forecasts for CymaBay Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:CBAY)
September 21, 2023 | finance.yahoo.com
CymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar on Clinical Outcomes in Patients with Cirrhosis due to Primary Biliary Cholangitis
September 21, 2023 | americanbankingnews.com
CymaBay Therapeutics (NASDAQ:CBAY) Trading Down 3.5% Following Insider Selling
September 20, 2023 | finance.yahoo.com
Insider Sell: Charles Mcwherter Sells 21,746 Shares of CymaBay Therapeutics Inc (CBAY)
September 26, 2023 | Chaikin Analytics (Ad)
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
September 15, 2023 | finance.yahoo.com
CymaBay Therapeutics to Present at the Cantor Global Healthcare Conference
September 14, 2023 | finance.yahoo.com
CymaBay Announces Closing of Upsized $258.7 Million Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 12, 2023 | finance.yahoo.com
Why CymaBay Therapeutics Stock Triumphed Again on Tuesday
September 12, 2023 | finance.yahoo.com
CymaBay Announces Pricing of Upsized $225 Million Public Offering of Common Stock and Pre-Funded Warrants
September 11, 2023 | markets.businessinsider.com
JonesTrading Remains a Buy on CymaBay Therapeutics (CBAY)
September 11, 2023 | markets.businessinsider.com
CymaBay Launches Public Offering Of $150 Mln Of Shares, Warrants
September 8, 2023 | finance.yahoo.com
CymaBay (CBAY) Stock Up on Positive Results From PBC Study
September 8, 2023 | finance.yahoo.com
Why CymaBay, With 159% Growth This Year, Just Surged For A Second Day Running
September 8, 2023 | seekingalpha.com
CymaBay Therapeutics: Shares Jump On Confirmatory Seladelpar Data - As Good As It Gets?
September 7, 2023 | msn.com
Raymond James Maintains Cymabay Therapeutics (CBAY) Strong Buy Recommendation
September 7, 2023 | markets.businessinsider.com
B.Riley Financial Sticks to Their Buy Rating for CymaBay Therapeutics (CBAY)
September 7, 2023 | marketwatch.com
CymaBay Shares Leap Premarket on Phase 3 Seladelpar Study Success >CBAY
September 7, 2023 | msn.com
CymaBay says liver disease candidate outperformed in Phase 3 trial
September 7, 2023 | markets.businessinsider.com
CymaBay Therapeutics' Lead Drug Candidate Hits Main Goal In Pivotal Study For Liver Damage
September 7, 2023 | finance.yahoo.com
CymaBay's Seladelpar Achieves High Statistical Significance for the Primary and Key Secondary Endpoints in the Phase 3 RESPONSE Trial in Primary Biliary Cholangitis
September 6, 2023 | finance.yahoo.com
CymaBay to Host Investor Call to Share Topline Results from the Phase 3 RESPONSE Trial of Seladelpar in Primary Biliary Cholangitis on September 7, 2023
September 6, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: CymaBay Therapeutics (CBAY) and VistaGen Therapeutics (VTGN)
August 29, 2023 | finanznachrichten.de
CymaBay Therapeutics, Inc.: CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
See More Headlines
Receive CBAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CBAY Company Calendar

Last Earnings
8/10/2023
Today
9/26/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CBAY
CUSIP
N/A
CIK
1042074
Web
www.cymabay.com
Phone
(510) 293-8800
Fax
510-293-9090
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.82
High Stock Price Forecast
$33.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+24.4%
Consensus Rating
Buy
Rating Score (0-4)
3.08
Research Coverage
12 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.88)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-106,000,000.00
Net Margins
N/A
Pretax Margin
-260.27%
Return on Equity
-104.52%
Return on Assets
-41.77%

Debt

Debt-to-Equity Ratio
0.92
Current Ratio
12.52
Quick Ratio
12.52

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.43 per share
Price / Book
35.86

Miscellaneous

Outstanding Shares
110,360,000
Free Float
102,631,000
Market Cap
$1.70 billion
Optionable
Optionable
Beta
0.35
The Best High-Yield Dividend Stocks for 2023 Cover
The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Sujal A. Shah (Age 50)
    Pres, CEO & Director
    Comp: $1.04M
  • Dr. Charles A. McWherter Ph.D. (Age 68)
    Pres of R&D and Chief Scientific Officer
    Comp: $700.65k
  • Mr. Paul T. Quinlan (Age 60)
    Gen. Counsel, Chief Compliance Officer & Corp. Sec.
    Comp: $629.72k
  • Mr. Harish Shantharam C.F.A.
    Chief Financial Officer
  • Mr. Ken Boehm
    Sr. VP of HR
  • Mr. Patrick J. O'Mara (Age 62)
    Sr. VP of Bus. Devel.
  • Dr. Robert L. Martin (Age 61)
    Sr. VP of Manufacturing & Nonclinical Devel.
  • Ms. Klara A. Dickinson-Eason (Age 55)
    Chief Regulatory & Quality Assurance Officer
  • Ms. Becki Filice (Age 62)
    Sr. VP of Portfolio & Product Leadership
  • Mr. Lewis J. Stuart B.A. (Age 64)
    BA, M.B.A., MBA, Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













CBAY Stock - Frequently Asked Questions

Should I buy or sell CymaBay Therapeutics stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last twelve months. There are currently 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CBAY shares.
View CBAY analyst ratings or view top-rated stocks.

What is CymaBay Therapeutics' stock price forecast for 2023?

12 analysts have issued 12-month price targets for CymaBay Therapeutics' shares. Their CBAY share price forecasts range from $12.00 to $33.00. On average, they anticipate the company's share price to reach $19.82 in the next twelve months. This suggests a possible upside of 28.5% from the stock's current price.
View analysts price targets for CBAY or view top-rated stocks among Wall Street analysts.

How have CBAY shares performed in 2023?

CymaBay Therapeutics' stock was trading at $6.27 at the beginning of the year. Since then, CBAY shares have increased by 145.9% and is now trading at $15.42.
View the best growth stocks for 2023 here.

Are investors shorting CymaBay Therapeutics?

CymaBay Therapeutics saw a decrease in short interest in August. As of August 31st, there was short interest totaling 8,960,000 shares, a decrease of 21.1% from the August 15th total of 11,350,000 shares. Based on an average daily volume of 2,410,000 shares, the short-interest ratio is currently 3.7 days.
View CymaBay Therapeutics' Short Interest.

When is CymaBay Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our CBAY earnings forecast.

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) posted its quarterly earnings data on Thursday, August, 10th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.20. The biopharmaceutical company had revenue of $31.02 million for the quarter, compared to analysts' expectations of $30.78 million.

What ETFs hold CymaBay Therapeutics' stock?

ETFs with the largest weight of CymaBay Therapeutics (NASDAQ:CBAY) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), SPDR S&P Pharmaceuticals ETF (XPH), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and ALPS Medical Breakthroughs ETF (SBIO).iShares Micro-Cap ETF (IWC).

What other stocks do shareholders of CymaBay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX).

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

Who are CymaBay Therapeutics' major shareholders?

CymaBay Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.70%), Cormorant Asset Management LP (3.87%), Perceptive Advisors LLC (3.80%), Franklin Resources Inc. (3.36%), State Street Corp (2.35%) and Geode Capital Management LLC (1.90%). Insiders that own company stock include Charles Mcwherter, Daniel Menold, Dennis D Kim, Paul T Quinlan and Sujal Shah.
View institutional ownership trends.

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CymaBay Therapeutics' stock price today?

One share of CBAY stock can currently be purchased for approximately $15.42.

How much money does CymaBay Therapeutics make?

CymaBay Therapeutics (NASDAQ:CBAY) has a market capitalization of $1.70 billion. The biopharmaceutical company earns $-106,000,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis.

How can I contact CymaBay Therapeutics?

CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The official website for the company is www.cymabay.com. The biopharmaceutical company can be reached via phone at (510) 293-8800, via email at investors@cymabay.com, or via fax at 510-293-9090.

This page (NASDAQ:CBAY) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -